Lightspeed Venture Partners and Sutter Hill Ventures led the round with participation from Clarus Ventures and GV (formerly Google Ventures). Forty Seven has also licensed the rights from
Makena is indicated to lower the risk of preterm birth in women who are pregnant with one baby and who have spontaneously delivered one preterm baby earlier. The
In its refuse to file letter, the agency stated that PTC’s application was insufficient to permit a substantive review. The company said it is reviewing its content to
Researchers at Texas Children’s Hospital and Houston Methodist Hospital developed the test that identifies the genetic material of the Zika virus. The tests, which can be carried out
Under the terms of the deal, Unilife grants Amgen exclusive rights to its wearable injectors within select drug classes for use with certain Amgen drugs. Amgen will also
The sNDA includes findings from the phase 2 Terrain and Strive studies, to update the appropriate clinical sections within the existing indication. The FDA approved enzalutamide to treat
The phase 3 ONCEMRK study, which is assessing Isentress in earlier untreated HIV-1 infected adults, met its primary efficacy endpoint by demonstrating that 1200mg of Isentress once-daily was
Sectoral Asset Management and existing investors participated in the new funding round. In total, Effector has raised around $111m since its establishment in 2013. Effector’s lead compound is
In the phase III Ratify trial, patients who received PKC412 and chemotherapy experienced an increase in median overall survival compared to those receiving chemo alone (74.7 months versus
Under the trial, which is being undertaken in Stockholm, Sweden, two higher doses and volumes of BPZE1, 108 CFU and 109 CFU, will be studied as a follow-up
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.